HUE032820T2 - Pirazolopiridazinok és eljárás degeneratív retina betegségek és Usher szindrómával társult hallásvesztés kezelésére - Google Patents
Pirazolopiridazinok és eljárás degeneratív retina betegségek és Usher szindrómával társult hallásvesztés kezelésére Download PDFInfo
- Publication number
- HUE032820T2 HUE032820T2 HUE12777328A HUE12777328A HUE032820T2 HU E032820 T2 HUE032820 T2 HU E032820T2 HU E12777328 A HUE12777328 A HU E12777328A HU E12777328 A HUE12777328 A HU E12777328A HU E032820 T2 HUE032820 T2 HU E032820T2
- Authority
- HU
- Hungary
- Prior art keywords
- compound
- mmol
- pyrazolo
- chloro
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (3)
- sba&ajiaiaií igénypontok L Formula 1! képiéit vegyülat:^Cffriiid M vttgy értitek pSfÄMi|Äii§Ä0 kőj:% âkgl l iai jéjérklsé Ό, 4¾ -g vagy 4¾¾ X értékű 0 5 terjedő égés.* ssâsn; Ej jétergésé egyébként: éf égytMxiö! iSggúllégöl RBk "Pf sf* A> *£»·*<% ÄH, GGCGCé Äik -CJN, -CFi, ·€{0)ΝΙΗ<;Η;}, vagy ·€:::€€!gOli; y értéké ti - 5 tmjédo égésé sÄR RyjeteÄse «gyesiként és egymástól fö|ygstIsÄÄk -F, >Br, álkik 4GC· -Cs sikil. *€N, -CfG * Cí 0)NHlCH;)f vagy -C:::CCHíOH; R:, jofatééé 41, -C···<';; .aikik·4ÂCé alkllérsg-ténik -{G-O, HkllGiGHG-IG alkiljí ää Âémk gGrCy â|k;l|éîR-GfO)R4S 4G C<; álkllénj-lj,ki jvkxuéso -UH ü-ií.YG aikin -NIG -ΝΊ t{G-G alkily -NUüG-é'·, alkéeoyééh. GRíiCVG. áik|lék)N(€rCu:úikklG äGä a|ki|_)|(CpCgÄilÄ}C^):?:"^{Cvä-Ck 4ÉKtI)((€*~Q, ÄIÄÄÄkk élktíg), -HlííC s 4¾ g Iki lég}-€k(C i*Ç$: ÄM%3 érték«; () - 10 323mjg értéke 0 - § iensdô egész szám; é értéke 0 - 6 lerféd# sgééZ'sgám; és 1¾¾ jéfeídds©Z*. Ä3 - j:pépÿp<5tït s^riïïêi v&g:v; 0 fst^ :viîfÿ: ég# gyogvÄr^sagitleg sî5p. :l Fonmk« H1 kégMtf vegvüles:Pörmsia 11! vagy s-nask gy^gysaerészetíkf'alkalmaahátó' séja* iii£s!;lMje!«nt|se -Cl -P. C vagy BC 54:.érté-ka'6*.5 svr-ÇB sgésx szim; % jviemisé vayniiMai és ë^«ï#tôi fkgptiÄl CI, By C Cr, C)C:CMi, C-CVC Äfi CC " OB, -CiOjNHiCH;}, vagy - Ry jélénîésé Bi, C;Ck ÄH, BPrC a!kI!ea)CM5 Ällenkfönlf, BCiCe &IkÜ4ÇCRôrC alki I), C; Cö ai kg&ij, -{C s C4 jBkiMÇC(€>) IC, 4P rC:IC jCnnticse Oli, CRÇ^Ck dkH), CBk CBfCvCs, alkitj, Cli((CCe áIkli#!)Cf-ík CJi((€v"Ck álk lié« JNC s Cs aI k BB(€ ä Cö ss !kR){|C) C* sík II in) CM};; : C(€ s -:5¾ alkl1}(|C $ *A-alfei !in>H|€ ;C klklliîlf CHICî Ce §lkilis)CRCy€s áikk)>s ëîtéfcs 8 - H) tesjiídö gpés: siáin; b értéke 8 ~ 1 téRéíté égésé s/isb; c énébe 0 ·· b egésï s?in»; Kijelentéseés és Kijelentése egywfc&H és egymástól tHggéHéfibl H vagy -k mal a megszórhassak hfgy &s R? közül legalább « sgylk jelentése -1. és ahol ha R:s jehmtese -CrC* alhil abket R ·> jelentésied. 4. Λ 3. Igénypont szerinti vegyalet, amelynek szerkezete. iívíí||alkalmazható
- 5. Kósatímeny, amdv nnbm.uza αν M , 13.. t-t e\ mony nont<A hatmolyike *,\ίγοχΜ\oa> nietet %>."' X me* avegyáv u K ' ti m ;\4o .< pár u m *»*> h é^p er >, m^í !í i\ Immo/em-, jgo vagy x ivöanyagot.4, Az 1--4., .13,, M. és 15, igénypontok bármelyike s/einttt vôgyuicî'^-a|y'':'étïÂ#.':^^â|^ttilag aî* kalnwhoto xya beatme me u m, Mu 'Vg> \ kezeim elsaraskm történő olUlmazo-na, amely ka fák maa»:« s lépest, hogy «st igényli! egyénnek az 1--4,t 1¾ 14. és 15. Igéhypótók bármelyike szerinti vegyület vagy ennek gvógyászaiikg alkalmazható sója hatékony mennyiségét adagoljak. 7. a ö, igénypont szerinti vegyidet vagy ennek gyégysaejesaelileg alkalmazható sója a? adott alkal mazásra, ahol a tlegeneradv retina betegség retinitis pigmentosa, l..eber--tele kongenhális -tm&urosss, Mláá vagy 1lsh#iztndréöm, 8, à 7 . igénypont szertnií vegyít le t vagy etïimk gyógyszerészetllei alksImazhstS slja az adod atkák snaánSívs, ahol az lAhet szimlomu IMtet 1 iShet 11 vagy IHher Ml szindróma, V \o xtntx< mn on tkf \ o i ‘"o us 1 k xS hx '<*'''> -< v ^ ndotwMM mazásra, aha) n öegeoerati-, retina betegség Usher Hl szhsdrom·.!, Η). Λζ M . la . bt 4.» bt igénypontok bármelyike szerinti tégy lilét vagy ennek gyógyászat; lag alkalmazható séta Usher szntUrómáhoe társait bal las vesztés kezelési eljárásba«:MM#^«lítaÍ»i&^'at a;nely tartalmazz# azt a lépést, hogy ezt igényid egyetmek m 1 -4., 13., 14. és IS. igénypontok bánne--,\e -zeroes xxíouk;' \a,.\ e. ; xV -póx\Ό \1 tm . oahonrhMe ,>n<> t-stekoto ποολ>x<,get a.d<v->l juk. IL.â m .ItillHí! vvgydtvt vágj? ássak gÿ<^$£i$ép^|ii$g 4k &#ft #|~. kàlmi^svav ^&ô^ ?» llslîi^ 'mnàtèm& ÖskerR Üshsrîl asgy OMsm II! samdlÄs, II, Λ 10, ig#hypmiiaamlsk vegyiket vagy ganek gyégvsasrésaeyigg álkaíigáaliaió sg|:s Molt si-kaggaKisvtj SkglM üshet yemdndaiâ Üshet 11! yemdrösse I:'|,: Formaié l-Y Mpletä vegvök·»:FíiSTVuia SV vagy ennek gyegyvaeresaetkeg alk&Iseaahsfô s6|s, ahal R* jsJehtèse -CgCj sikk.
- 14. Vegyöfeg amelynek. s vetkezem:vagyvagy etek gyôgÿsasrmaeîilag afkaimaidíMo tója. 11 Ax' L vagy 3· Igáliypotg ékánail vegyület vggyennek i a eneke 0 -- à íetjedő egáxa vzárm és h 4rtékv 0 - 4 iygíedö egk&y szám.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478642P | 2011-04-25 | 2011-04-25 | |
US201161537908P | 2011-09-22 | 2011-09-22 | |
US201161576471P | 2011-12-16 | 2011-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE032820T2 true HUE032820T2 (hu) | 2017-11-28 |
Family
ID=47072720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE12777328A HUE032820T2 (hu) | 2011-04-25 | 2012-04-25 | Pirazolopiridazinok és eljárás degeneratív retina betegségek és Usher szindrómával társult hallásvesztés kezelésére |
Country Status (11)
Country | Link |
---|---|
US (5) | US9079909B2 (hu) |
EP (1) | EP2701510B1 (hu) |
JP (2) | JP5902293B2 (hu) |
AU (1) | AU2012249801B2 (hu) |
CA (1) | CA2834049C (hu) |
ES (1) | ES2625534T3 (hu) |
HU (1) | HUE032820T2 (hu) |
IL (1) | IL229023A (hu) |
PL (1) | PL2701510T3 (hu) |
WO (1) | WO2012148994A1 (hu) |
ZA (1) | ZA201307961B (hu) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012249801B2 (en) | 2011-04-25 | 2016-05-19 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome |
EP2911671B1 (en) * | 2012-10-25 | 2018-06-27 | Usher III Initiative | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
US8765762B2 (en) | 2012-10-25 | 2014-07-01 | Usher III, Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome |
PL2912038T3 (pl) * | 2012-10-25 | 2019-02-28 | Usher Iii Initiative, Inc. | Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera |
AU2016274956A1 (en) * | 2015-06-11 | 2017-12-14 | Usher Iii Initiative, Inc. | Methods of treating or preventing a proteopathy |
WO2021080508A1 (en) * | 2019-10-23 | 2021-04-29 | National University Of Singapore | Method and system for synthesising compounds |
WO2022011091A1 (en) * | 2020-07-09 | 2022-01-13 | Usher Iii Initiative, Inc. | Treatment of cancer, inflammatory diseases and autoimmune diseases |
WO2023101421A1 (ko) * | 2021-12-03 | 2023-06-08 | (주)인비보텍 | 난청 또는 이명의 예방 또는 치료용 조성물 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1435957B1 (en) | 2001-04-30 | 2009-06-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes |
GB0206723D0 (en) * | 2002-03-21 | 2002-05-01 | Glaxo Group Ltd | Novel compounds |
WO2006050109A2 (en) * | 2004-10-29 | 2006-05-11 | Abbott Laboratories | Novel kinase inhibitors |
AU2005327921A1 (en) | 2004-11-01 | 2006-08-31 | University Of Southern California | Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
WO2006077401A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Pyrrolopyridines useful in the treatment of inflammation |
AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
US20070123508A1 (en) * | 2005-05-27 | 2007-05-31 | Roger Olsson | PAR2-modulating compounds and their use |
WO2007075911A2 (en) * | 2005-12-22 | 2007-07-05 | Yale University | Inhibition of glycogen synthase kinase and methods of treating autoimmune or immune inflammatory disease |
CA2648196A1 (en) * | 2006-04-14 | 2007-10-25 | Novartis Ag | Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders |
CN101528744A (zh) | 2006-10-20 | 2009-09-09 | Irm责任有限公司 | 用于调节c-kit和pdgfr受体的组合物和方法 |
WO2009039420A1 (en) * | 2007-09-21 | 2009-03-26 | Medivation Neurology, Inc. | Methods and compositions for treating neuronal death mediated ocular diseases |
AU2008323694A1 (en) | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
CA2986640C (en) | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
DE102008052943A1 (de) * | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
AU2010356144B2 (en) | 2010-06-24 | 2015-06-04 | Alphabeta Ab | Compound and method for treatment of Alzheimer's disease and familial dementia |
AU2012249801B2 (en) | 2011-04-25 | 2016-05-19 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome |
EP2723384B1 (en) | 2011-06-22 | 2018-08-29 | The General Hospital Corporation | Treatment of proteinopathies |
US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
US8765762B2 (en) | 2012-10-25 | 2014-07-01 | Usher III, Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome |
PL2912038T3 (pl) | 2012-10-25 | 2019-02-28 | Usher Iii Initiative, Inc. | Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera |
EP2911671B1 (en) | 2012-10-25 | 2018-06-27 | Usher III Initiative | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
AU2016274956A1 (en) | 2015-06-11 | 2017-12-14 | Usher Iii Initiative, Inc. | Methods of treating or preventing a proteopathy |
-
2012
- 2012-04-25 AU AU2012249801A patent/AU2012249801B2/en active Active
- 2012-04-25 CA CA2834049A patent/CA2834049C/en active Active
- 2012-04-25 ES ES12777328.1T patent/ES2625534T3/es active Active
- 2012-04-25 WO PCT/US2012/034959 patent/WO2012148994A1/en active Application Filing
- 2012-04-25 EP EP12777328.1A patent/EP2701510B1/en active Active
- 2012-04-25 PL PL12777328T patent/PL2701510T3/pl unknown
- 2012-04-25 HU HUE12777328A patent/HUE032820T2/hu unknown
- 2012-04-25 JP JP2014508507A patent/JP5902293B2/ja active Active
-
2013
- 2013-03-08 US US13/791,205 patent/US9079909B2/en active Active
- 2013-10-22 IL IL229023A patent/IL229023A/en active IP Right Grant
- 2013-10-24 ZA ZA2013/07961A patent/ZA201307961B/en unknown
-
2015
- 2015-06-04 US US14/730,994 patent/US9260381B2/en active Active
- 2015-12-28 US US14/980,347 patent/US9549910B2/en active Active
-
2016
- 2016-03-08 JP JP2016044089A patent/JP2016193884A/ja active Pending
- 2016-12-12 US US15/375,959 patent/US9925187B2/en active Active
-
2018
- 2018-03-19 US US15/924,831 patent/US10307422B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9925187B2 (en) | 2018-03-27 |
AU2012249801B2 (en) | 2016-05-19 |
CA2834049A1 (en) | 2012-11-01 |
AU2012249801A1 (en) | 2013-11-07 |
CA2834049C (en) | 2018-05-22 |
EP2701510A1 (en) | 2014-03-05 |
PL2701510T3 (pl) | 2017-07-31 |
IL229023A0 (en) | 2013-12-31 |
JP2014515758A (ja) | 2014-07-03 |
US20170143718A1 (en) | 2017-05-25 |
US20130252936A1 (en) | 2013-09-26 |
WO2012148994A1 (en) | 2012-11-01 |
ZA201307961B (en) | 2015-12-23 |
US10307422B2 (en) | 2019-06-04 |
JP5902293B2 (ja) | 2016-04-13 |
ES2625534T3 (es) | 2017-07-19 |
US20150266812A1 (en) | 2015-09-24 |
US20180207159A1 (en) | 2018-07-26 |
IL229023A (en) | 2017-07-31 |
US20160158172A1 (en) | 2016-06-09 |
US9549910B2 (en) | 2017-01-24 |
EP2701510A4 (en) | 2014-06-11 |
EP2701510B1 (en) | 2017-02-15 |
US9260381B2 (en) | 2016-02-16 |
JP2016193884A (ja) | 2016-11-17 |
US9079909B2 (en) | 2015-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2701510B1 (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
US9783545B2 (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
EP2911671B1 (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | |
JP2021519278A (ja) | N−(3−(7H−ピロロ[2,3−d]ピリミジン−4−イル)フェニル)ベンズアミド誘導体 | |
KR20010083042A (ko) | 피롤로[2,3디]피리미딘 조성물 및 이의 용도 | |
TW200936591A (en) | Tricyclic compounds and use thereof | |
WO2004020414A1 (en) | Oxytocin inhibitors | |
PT2049477E (pt) | Moduladores da actividade do receptor da quimiocina, formas cristalinas e processo | |
AU2013334138B2 (en) | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome | |
US8765762B2 (en) | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome |